Indication
Type 1 diabetes mellitus
Type 1 diabetes mellitus is a chronic autoimmune metabolic disorder characterized by the targeted destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, resulting in absolute or near-absolute insulin deficiency. Read more about Type 1 diabetes mellitus
154 drugs 18 manufacturers
Drugs that treat it
Common Type 1 diabetes mellitus therapies.
NOVOLIN 70-30 FLEXPEN U-100 (insulin NPH human isophane/insulin regular, human)
BASAGLAR TEMPO PEN(U-100)INSLN (insulin glargine,human recombinant analog)
HUMALOG TEMPO PEN(U-100)INSULN (insulin lispro)
SEMGLEE(INSULIN GLARG-YFGN)PEN (insulin glargine-yfgn)
SEMGLEE(INSULIN GLARGINE-YFGN) (insulin glargine-yfgn)
LYUMJEV TEMPO PEN(U-100)INSULN (insulin lispro-aabc)
TZIELD (teplizumab-mzwv)
NOVOLIN 70/30 U-100 INSULIN (insulin NPH human isophane/insulin regular, human)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonType 1 diabetes mellitus is a chronic autoimmune metabolic disorder characterized by the targeted destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, resulting in absolute or near-absolute insulin deficiency.
Although it most frequently presents during childhood or adolescence, it can develop at any age.
Pathophysiologically, the disease involves genetic susceptibility and circulating islet-related autoantibodies that trigger immune-mediated insulitis.
This progressive loss of endogenous insulin leads to sustained hyperglycemia, altered carbohydrate, lipid, and protein metabolism, and an elevated risk of acute life-threatening complications such as diabetic ketoacidosis, alongside long-term microvascular and macrovascular pathology.
- nih.gov
Type 1 diabetes mellitus is a chronic autoimmune metabolic disorder characterized by the targeted destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, resulting in absolute or near-absolute insulin deficiency
- nih.gov
Type 1 diabetes mellitus is a chronic autoimmune metabolic disorder characterized by the targeted destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, resulting in absolute or near-absolute insulin deficiency Although it most frequently presents during childhood or adolescence, it can develop at any age Pathophysiologically, the disease involves genetic susceptibility and circulating islet-related autoantibodies that trigger immune-mediated insulitis
- nih.gov
Although it most frequently presents during childhood or adolescence, it can develop at any age This progressive loss of endogenous insulin leads to sustained hyperglycemia, altered carbohydrate, lipid, and protein metabolism, and an elevated risk of acute life-threatening complications such as diabetic ketoacidosis, alongside long-term microvascular and macrovascular pathology
- nih.gov
Pathophysiologically, the disease involves genetic susceptibility and circulating islet-related autoantibodies that trigger immune-mediated insulitis
- nih.gov
This progressive loss of endogenous insulin leads to sustained hyperglycemia, altered carbohydrate, lipid, and protein metabolism, and an elevated risk of acute life-threatening complications such as diabetic ketoacidosis, alongside long-term microvascular and macrovascular pathology
Personalize your experience
Follow Type 1 diabetes mellitus and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.